Investing.comCodex · 实盘不做把握 7/10
北京时间·🕒 发布 01:07:01时区推断·⟳ 抓取 01:07:41·⚡ 决策 07-28 01:08:26 +45s·91.9 天前
Malin将Kymab剩余或有对价减记至零，因Sanofi停止amlitelimab特应性皮炎开发
当前新增事实主要影响Malin对Kymab出售尾款的估值，文中剩余公允价值仅约330万欧元，量级过小。
📄 原文Investing.com↗ 原文
Malin writes down Kymab contingent consideration to zero
Oil prices tumble over amid halt to fighting between U.S., Iran DUBLIN - Malin Corporation (Euronext Growth Dublin:MLC)…
不做 Sanofi（SNY.US）
核心停开发消息已在上周四披露，本条只是Malin减记尾款的后续转述；对Sanofi量级不足且无新鲜edge，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-27 · 扩散 medium · price-in 风险 high ↗
关键理由
- 当前新增事实主要影响Malin对Kymab出售尾款的估值，文中剩余公允价值仅约330万欧元，量级过小。
- Sanofi停止amlitelimab特应性皮炎申报的核心消息已在上周四披露，本条对Sanofi不是新鲜增量。
- Malin为Euronext Growth Dublin标的，不在本策略主要可执行市场范围内，且Sanofi为超大药企，单一管线终止不足以形成短线可交易损害。
主要风险
- 若后续Sanofi确认amlitelimab其他适应症也全面终止，才可能重新评估其管线价值影响。
原文全文
展开原文 · 1,835 字
Oil prices tumble over amid halt to fighting between U.S., Iran
DUBLIN - Malin Corporation (Euronext Growth Dublin:MLC) said today it will write down the value of its remaining contingent consideration from the sale of Kymab to zero following Sanofi’s decision to halt development of amlitelimab for atopic dermatitis.
Sanofi (EURONEXT:SAN and NASDAQ:SNY) announced Thursday it will not submit amlitelimab, an OX40-ligand monoclonal antibody, for global regulatory reviews in moderate-to-severe atopic dermatitis. The decision followed a strategic pipeline assessment.
Sanofi determined the efficacy and safety data generated does not support further development of amlitelimab in atopic dermatitis. The company said the drug would not represent a meaningful improvement to the standard of care for patients, despite the ESTUARY phase 3 long-term extension study showing long-term maintenance of clinical response without relapse in patients aged 12 years and older.
Sanofi acquired Kymab in April 2021 for an upfront payment of approximately $1.1 billion and up to $350 million in contingent consideration tied to clinical and commercial milestones for amlitelimab. Malin owned approximately 10% of Kymab and received $112.7 million (€95.4 million) from the upfront payment. The company received an additional $7.1 million (€6.5 million) in contingent consideration in February 2024.
At December 31, 2025, Malin estimated the maximum remaining consideration it could receive at $7 million, with a fair value of €2.9 million. As of February 23, the fair value stood at €3.3 million.
The write-down will be disclosed as a post-period event in Malin’s 2026 interim financial statements, according to a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
DUBLIN - Malin Corporation (Euronext Growth Dublin:MLC) said today it will write down the value of its remaining contingent consideration from the sale of Kymab to zero following Sanofi’s decision to halt development of amlitelimab for atopic dermatitis.
Sanofi (EURONEXT:SAN and NASDAQ:SNY) announced Thursday it will not submit amlitelimab, an OX40-ligand monoclonal antibody, for global regulatory reviews in moderate-to-severe atopic dermatitis. The decision followed a strategic pipeline assessment.
Sanofi determined the efficacy and safety data generated does not support further development of amlitelimab in atopic dermatitis. The company said the drug would not represent a meaningful improvement to the standard of care for patients, despite the ESTUARY phase 3 long-term extension study showing long-term maintenance of clinical response without relapse in patients aged 12 years and older.
Sanofi acquired Kymab in April 2021 for an upfront payment of approximately $1.1 billion and up to $350 million in contingent consideration tied to clinical and commercial milestones for amlitelimab. Malin owned approximately 10% of Kymab and received $112.7 million (€95.4 million) from the upfront payment. The company received an additional $7.1 million (€6.5 million) in contingent consideration in February 2024.
At December 31, 2025, Malin estimated the maximum remaining consideration it could receive at $7 million, with a fair value of €2.9 million. As of February 23, the fair value stood at €3.3 million.
The write-down will be disclosed as a post-period event in Malin’s 2026 interim financial statements, according to a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。